Cargando…
Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future
Although the mortality rates of gastric cancer (GC) are gradually declining, gastric cancer is still the fourth leading cause of cancer-related death worldwide. This may be due to the high rate of patients who are diagnosed with GC at advanced stages. However, in countries such as Japan with endosco...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319225/ https://www.ncbi.nlm.nih.gov/pubmed/35877231 http://dx.doi.org/10.3390/curroncol29070371 |
_version_ | 1784755497749970944 |
---|---|
author | Hisada, Hiroyuki Sakaguchi, Yoshiki Oshio, Kaori Mizutani, Satoru Nakagawa, Hideki Sato, Junichi Kubota, Dai Obata, Miho Cho, Rina Nagao, Sayaka Miura, Yuko Mizutani, Hiroya Ohki, Daisuke Yakabi, Seiichi Takahashi, Yu Kakushima, Naomi Tsuji, Yosuke Yamamichi, Nobutake Fujishiro, Mitsuhiro |
author_facet | Hisada, Hiroyuki Sakaguchi, Yoshiki Oshio, Kaori Mizutani, Satoru Nakagawa, Hideki Sato, Junichi Kubota, Dai Obata, Miho Cho, Rina Nagao, Sayaka Miura, Yuko Mizutani, Hiroya Ohki, Daisuke Yakabi, Seiichi Takahashi, Yu Kakushima, Naomi Tsuji, Yosuke Yamamichi, Nobutake Fujishiro, Mitsuhiro |
author_sort | Hisada, Hiroyuki |
collection | PubMed |
description | Although the mortality rates of gastric cancer (GC) are gradually declining, gastric cancer is still the fourth leading cause of cancer-related death worldwide. This may be due to the high rate of patients who are diagnosed with GC at advanced stages. However, in countries such as Japan with endoscopic screening systems, more than half of GCs are discovered at an early stage, enabling endoscopic resection (ER). Especially after the introduction of endoscopic submucosal dissection (ESD) in Japan around 2000, a high en bloc resection rate allowing pathological assessment of margin and depth has become possible. While ER is a diagnostic method of treatment and may not always be curative, it is widely accepted as standard treatment because it is less invasive than surgery and can provide an accurate diagnosis for deciding whether additional surgery is necessary. The curability of ER is currently assessed by the completeness of primary tumor removal and the possibility of lymph node metastasis. This review introduces methods, indications, and curability criteria for ER of EGC. Despite recent advances, several problems remain unsolved. This review will also outline the latest evidence concerning future issues. |
format | Online Article Text |
id | pubmed-9319225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93192252022-07-27 Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future Hisada, Hiroyuki Sakaguchi, Yoshiki Oshio, Kaori Mizutani, Satoru Nakagawa, Hideki Sato, Junichi Kubota, Dai Obata, Miho Cho, Rina Nagao, Sayaka Miura, Yuko Mizutani, Hiroya Ohki, Daisuke Yakabi, Seiichi Takahashi, Yu Kakushima, Naomi Tsuji, Yosuke Yamamichi, Nobutake Fujishiro, Mitsuhiro Curr Oncol Review Although the mortality rates of gastric cancer (GC) are gradually declining, gastric cancer is still the fourth leading cause of cancer-related death worldwide. This may be due to the high rate of patients who are diagnosed with GC at advanced stages. However, in countries such as Japan with endoscopic screening systems, more than half of GCs are discovered at an early stage, enabling endoscopic resection (ER). Especially after the introduction of endoscopic submucosal dissection (ESD) in Japan around 2000, a high en bloc resection rate allowing pathological assessment of margin and depth has become possible. While ER is a diagnostic method of treatment and may not always be curative, it is widely accepted as standard treatment because it is less invasive than surgery and can provide an accurate diagnosis for deciding whether additional surgery is necessary. The curability of ER is currently assessed by the completeness of primary tumor removal and the possibility of lymph node metastasis. This review introduces methods, indications, and curability criteria for ER of EGC. Despite recent advances, several problems remain unsolved. This review will also outline the latest evidence concerning future issues. MDPI 2022-07-04 /pmc/articles/PMC9319225/ /pubmed/35877231 http://dx.doi.org/10.3390/curroncol29070371 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hisada, Hiroyuki Sakaguchi, Yoshiki Oshio, Kaori Mizutani, Satoru Nakagawa, Hideki Sato, Junichi Kubota, Dai Obata, Miho Cho, Rina Nagao, Sayaka Miura, Yuko Mizutani, Hiroya Ohki, Daisuke Yakabi, Seiichi Takahashi, Yu Kakushima, Naomi Tsuji, Yosuke Yamamichi, Nobutake Fujishiro, Mitsuhiro Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future |
title | Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future |
title_full | Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future |
title_fullStr | Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future |
title_full_unstemmed | Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future |
title_short | Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future |
title_sort | endoscopic treatment of superficial gastric cancer: present status and future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319225/ https://www.ncbi.nlm.nih.gov/pubmed/35877231 http://dx.doi.org/10.3390/curroncol29070371 |
work_keys_str_mv | AT hisadahiroyuki endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT sakaguchiyoshiki endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT oshiokaori endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT mizutanisatoru endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT nakagawahideki endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT satojunichi endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT kubotadai endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT obatamiho endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT chorina endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT nagaosayaka endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT miurayuko endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT mizutanihiroya endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT ohkidaisuke endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT yakabiseiichi endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT takahashiyu endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT kakushimanaomi endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT tsujiyosuke endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT yamamichinobutake endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture AT fujishiromitsuhiro endoscopictreatmentofsuperficialgastriccancerpresentstatusandfuture |